Sandoz announced today that its biosimilar rituximab product has been approved by the European Commission to treat blood cancers and immunological diseases.
Sandoz announced today that its biosimilar rituximab product has been approved by the European Commission to treat blood cancers and immunological diseases. Sandoz’s product will be marketed as both Rixathon and Riximyo under a duplicate marketing authorization.
Sandoz’s rituximab is approved for use in all indications of its reference, Roche’s MabThera, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
The European Commission based its approval on analytical, preclinical, and clinical data, including pharmacokinetic (PK) and pharmacodynamic (PD) data that demonstrated equivalent safety, efficacy, and quality of the biosimilar and reference treatments. Clinical studies for the biosimilar included a phase 3 efficacy and safety study in patients with previously untreated advanced follicular lymphoma. The study met its primary endpoint of demonstrating equivalence in overall response rate to the reference product, and additionally demonstrated similarity in efficacy, PK and PD.
"Today's approval of Rixathon represents a big win for patients in Europe with blood cancers or immunological diseases because it enables increased access to biologics,” said Carol Lynch, global head of biopharmaceuticals at Sandoz. “It also allows healthcare systems to redeploy resources to other areas of high need, particularly innovative therapies," Lynch added.
Sandoz’s product joins Celltrion’s Truxima, another biosimilar rituximab, in the European marketplace. Celltrion’s product, granted European authorization in February of 2017, has already been supplied to 50 hospitals in the United Kingdom. According to Celltrion, patient populations treated with Truxima included patients who were switched to the biosimilar. Competition from Sandoz and Celltrion poses a challenge to Roche, which relied on its innovative product for approximately $7.2 billion of its global sales in 2016.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.